Evidence map›Paper›PMID 30288042›Full record

ArticleInternational journal of nanomedicine2018

A drug eluting poly(trimethylene carbonate)/poly(lactic acid)-reinforced nanocomposite for the functional delivery of osteogenic molecules.

Xi Zhang, Mike A Geven, Xinluan Wang, Ling Qin, Dirk W Grijpma, Ton Peijs, David Eglin, Olivier Guillaume, Julien E Gautrot

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xi ZhangSchool of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London, UK, j.gautrot@qmul.ac.uk.
Mike A GevenDepartment of Biomaterials Science and Technology, University of Twente, Enschede, the Netherlands.
Xinluan WangTranslational Medicine R&D Center, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 5018057, China.
Ling QinTranslational Medicine R&D Center, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 5018057, China.
Dirk W GrijpmaDepartment of Biomaterials Science and Technology, University of Twente, Enschede, the Netherlands.
Ton PeijsSchool of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London, UK, j.gautrot@qmul.ac.uk.
David EglinAO Research Institute Davos, Davos, Switzerland, olivier.guillaume@aofoundation.org.
Olivier GuillaumeAO Research Institute Davos, Davos, Switzerland, olivier.guillaume@aofoundation.org.
Julien E GautrotSchool of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London, UK, j.gautrot@qmul.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoly(trimethylene carbonate) (PTMC) has wide biomedical applications in the field of tissue engineering, due to its biocompatibility and biodegradability features. Its common manufacturing involves photofabrication, such as stereolithography (SLA), which allows the fabrication of complex and controlled structures. Despite the great potential of SLA-fabricated scaffolds, very few examples of PTMC-based drug delivery systems fabricated using photo-fabrication can be found ascribed to light-triggered therapeutics instability, degradation, side reaction, binding to the macromers, etc. These concerns severely restrict the development of SLA-fabricated PTMC structures for drug delivery purposes.

methodsIn this context, we propose here, as a proof of concept, to load a drug model (dexamethasone) into electrospun fibers of poly(lactic acid), and then to integrate these bioactive fibers into the photo-crosslinkable resin of PTMC to produce hybrid films. The hybrid films' properties and drug release profile were characterized; its biological activity was investigated via bone marrow mesenchymal stem cells culture and differentiation assays.

resultsThe polymer/polymer hybrids exhibit improved properties compared with PTMC-only films, in terms of mechanical performance and drug protection from UV denaturation. We further validated that the dexamethasone preserved its biological activity even after photoreaction within the PTMC/poly(lactic acid) hybrid structures by investigating bone marrow mesenchymal stem cells proliferation and osteogenic differentiation.

conclusionThis study demonstrates the potential of polymer-polymer scaffolds to simultaneously reinforce the mechanical properties of soft matrices and to load sensitive drugs in scaffolds that can be fabricated via additive manufacturing.

Indexed as

Drug Delivery SystemsOsteogenesisCell DifferentiationCell ProliferationDexamethasoneDioxanesDrug LiberationHumansMesenchymal Stem CellsNanocompositesNanofibersPolyestersPolymersTissue EngineeringTissue ScaffoldsDexamethasoneDioxanesPolyesterspoly(lactide)Polymerspolytrimethylene carbonatedexamethasonefiber-reinforced compositeosteogenic materialsphoto-crosslinkingpoly(trimethylene carbonate)

Identifiers

PMID30288042
PMCPMC6161751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.